SNX-III (NEUREX Corporation, Menlo Park, CA, U.S.A.) an w-conopeptide, was tested for cy toprotection following normothermic ischemia using both a four-vessel occlusion model of severe forebrain isch emia and a model of transient middle cerebral artery oc clusion focal ischemia. Adult male Wi star rats were sub jected to 10 min of forebrain ischemia followed by 7 days of reperfusion. A single dose of SNX-Ill (5 mg/kg) was injected intravenously following delays of either 6 or 24 h after reperfusion. For I I rats treated with saline, there was 78 ± 13% CAl neuronal injury (mean ± SD); for I I given SNX-lli delayed by 6 h, injury was reduced to 35 ± 30% (p < 0.01); and remarkably; treatment delayed by 24 h (n = 10), still resulted in protection, with only 50 ± 29% injury (p < 0.05). Adult male spontaneously hyper tensive rats had transient occlusion of the right middle cerebral artery of 1.5-or 2-h duration followed by 22.5 or 22 h of reperfusion, respectively. Rats were randomly assigned to receive either saline or SNX-I I I (5 mg/kg i.v.), with treatment starting immediately after reperfu sion (I.5-h ischemic group) or at I h following the onset of
The early release of excitatory amino acids (Ben veniste et ai., 1984; Globus et ai., 1988a, b; Manev et aI., 1990; Benveniste, 1991) as a critical link to the ensuing Ca 2 + -dependent cascade (Siesj6, 1986; Uematsu et aI., 1988 Uematsu et aI., , 1989 Siesj6 and Bengtsson, ischemia (2-h ischemic group) . In the 1.5-h ischemic group, saline-treated animals sustained 138 ± 32 mm3 of neocortical infarction (n = 9), and SNX-lli treatment resulted in an infarct reduction to 76 ± 25 mm3 (n = 9; p < 0.001). In the 2-h ischemic group, saline-treated con trols sustained 21 I ± 51 mm3 (n = 6) of infarction, and SNX-III infusion attenuated the infarct size to 126 ± 50 mm3 (n = 5; p < 0.05). Because of the hypotensive ef fects of SNX-III, an additional SNX-lll-treated group with intravenous norepinephrine blood pressure support was studied, using 2 h of focal ischemia and 22 h of reper fusion. In this group, combined treatment resulted in 141 ± 22 mm3 of infarction (n = 5; p < 0.05). These data suggest that Ca2 + fluxes through w-conopeptide-sensitive N-type Ca2+ channels are critically involved in the patho genesis of selective neuronal death up to 24 h after isch emia in the hippocampus and that this conopeptide pro tection extends, even when given late, to neocortical in farct reduction. Key Words: CAl cells-Conopeptide Glutamate-N-Type Ca2+ channel blockers-Rats Stroke.
1989; Choi, 1991) that results in delayed postisch ernie destruction of CAl neurons (Pulsinelli et aI., 1982) should be considered in the light of the evi dence that has been generated through the use of markedly delayed, and yet still neuroprotective, treatments with both an u-amino-3-hydroxy-5methyl-4-isoxazole (AMPA) antagonist (Diemer et aI., 1992; Li and Buchan, 1993; Nellgard and Wie loch, 1993) and the w-conopeptides (Valentino et aI., 1993) . The conopeptide, SNX-ll1, which is a synthetic peptide derived from MVIIA toxin, iso lated from Conus magus venom (Olivera et aI., 1985 (Olivera et aI., , 1990 , is a potent competitive inhibitor of Ca 2 + neuronal entry through N-type Ca 2 + channels (Ramachandran et aI., 1992) . Widely distributed in the central nervous system, these Ca 2 + channels seem to be located primarily presynaptically (Reyn olds et aI., 1986; McCleskey et aI., 1987) and regu late transmitter efflux (Dooley et aI., 1988) during ischemia and possibly during the prolonged period of 24-48 h prior to irreversible neuronal injury. Ini tial studies (Valentino et aI., 1992) suggest not only that postischemic blockade of N-type Ca 2 + chan nels with the conopeptide derivative SNX-lll is highly protective for CAl cells, but that delaying the start of the therapy, i.e., giving it at 6 versus 1 h following ischemia, results in greater neuropro tection (Valentino et aI., 1993) .
Early data suggest that SNX-lll may prevent not only hippocampal (Valentino et aI., 1991; Buchan et aI., 1993a) , but also neocortical (Smith and Siesjo, 1993) neuronal injury following transient severe forebrain ischemia. Focal ischemia induces both dense or core regions of ischemia and perifocal or penumbral regions where flow reductions, while re sulting in changes in electrical activity, may not cause a complete loss of energy charge and may create a population of neurons that remain viable if blood flow is returned quickly enough (Siesjo, 1992a) . Following an initial recovery of energy, there may be a continued accumulation of lactate and Ca 2 + until the tissue infarcts (Siesjo, 1992a, b) . These "threatened" neurons may therefore die through pathogenic mechanisms similar to those that result in selective neuronal death of neurons in the wake of global ischemia such as hippocampal CAl cells (Pulsinelli et aI., 1982) and thus may be protected by similar mechanisms that prevent se lective neuronal death (Siesjo and Bengtsson, 1989) . Similarly to SNX-lll, intraischemic hypo thermia (Xue et aI., 1992) , and the selective AMPA antagonist 2,3-dihydroxy-6-nitro-7 -sulfamoyl benzo(F)quinoxaline (NBQX) (Buchan et aI., 1991) , can be used even if initial treatment is delayed fol lowing the onset of ischemia to reduce Ca 2 + accu mulation and prevent the reperfused penumbral tis sue infarcting.
Using an established "delayed" cytoprotective dose of SNX-ll1 against selective neuronal injury of CAl cells (Valentino et aI., 1993) , we went on to test delayed SNX-111 treatment for its abilities to attenuate the size of a neocortical infarct produced in hypertensive rats by transient middle cerebral artery occlusion (MCAo). Some of these data have been presented in abstract form (Buchan et aI., 1993 (Buchan et aI., , 1994 Xue et aI., 1993) .
MATERIALS AND METHODS

Global ischemia
Male Wistar rats weighing 150-250 g were prepared using modified four-vessel occlusion (4VO) surgery J Cereb Blood Flow Metab. Vol. 14, No.6, 1994 (Pulsinelli and Buchan, 1988) . These methods have re cently been described in detail , but in brief, under halothane anesthesia, both vertebral arter ies were cauterized, and reversible ligatures were placed around both common carotids and around the muscula ture to prevent any collateral cephalic circulation. The wounds were closed, and animals were returned to their cages and allowed free access to water, but not food, overnight. Animals that met the criteria for ischemia (un responsiveness and pupillary dilatation) during the 10 min of 4VO, with temperature maintenance at 37.5 ± OSC, were reperfused by removing the carotid clamps and the collateral snare. Rectal temperature was controlled dur ing ischemia and reperfusion by a rectal thermistor probe connected to a heat lamp. Brain temperature was previ ously found to be 0.5-I.0°C lower than body temperature (Xue et aI., 1992) . Following recovery from ischemia and recovery of temperature homeostasis, rats were random ized to one of three treatment groups. (I) The saline con trol group consisted of II animals that received 1 ml of normal saline intravenously (i. v.) over a period of 15 min, 6 h following reperfusion. (2). The SNX-Ill 6-h delay group comprised 13 rats that received SNX-111, 5 mg/kg, 1 mg in I ml of normal saline, infused i.v. over 15 min, 6 h following reperfusion. (3) The SNX-lll 24-h delay group was 10 rats that were given the same dose of SNX III i. v. after a delay of 24 h following reperfusion.
Following infusion of either saline or SNX-Ill, animals were carefully monitored for 6 h with the temperature maintained throughout. Animals were subsequently al lowed to survive for 7 days, then reanesthetized and per fusion-fixed. Seven-micro meter-thick sections through the dorsal hippocampus were stained with hematoxylin and eosin, and normal-appearing and injured CAl cells were counted. The percentage of necrotic neurons was calculated for CAl and expressed as mean ± SD. This resulted in a nonparametric data set. Arcsin and logit transformation failed to normalize the data, so percentage injury using Kruskal-Wallis and Mann-Whitney U tests with Bonferonni corrections was calculated (Zar, 1984 ). An a priori sample size calculation, using an expected mean of 80 ± 20% (mean ± SD) for CAl injury in our laboratory , predicted that to avoid missing a difference of 30% between groups (with ex = 0.05 and 13 = 0.2), 10 animals were needed per group.
Focal ischemia
Male spontaneously hypertensive rats (SHR) weighing 225-300 g were deprived of food but allowed free access to water the night prior to surgery. Surgery has been de scribed in detail (Buchan et aI., 1992) , but in short, under halothane anesthesia the right common carotid artery (CCA) was ligated and a burr hole 1 mm in diameter was drilled 2-3 mm rostral to the point of fusion of the zygo matic arch with the temporal bone (Brint et aI., 1988) to expose the MCA so that a prototype No. 1 microaneu rysm clip (Codman, Boston, MA, U.S.A.) could be placed on the MCA proximal to the point where it crosses the inferior cerebral vein in the rhinal fissure. Animals were subjected to either 1.5 or 2 h of ischemia (during which time the anesthesia was interrupted), at the end of which, under a brief anesthesia, the MCA clip was re moved. The temperature was maintained at 37.5 ± OSC throughout and physiological conditions (arterial blood pressure, arterial blood gases, plasma glucose, and he matocrit) were recorded just prior to ischemia, immedi-ately after reperfusion, and just prior to sacrifice at 24 h. Regional cerebral blood flow (rCBF) was also recorded using laser Doppler flowmetry (LDF) over the core and edge regions where infarcts develop prior to MCAo. Rel ative changes in CBF as a percentage of baseline flows (Dirnagl et aI., 1989) were then measured over both the core and the edge of the ischemic territory in the right neocortex at the start of ischemia and blood flow was measured at the end of ischemia and at the time of death (24 h). Burr holes were drilled, one 4 mm dorsal to the exposure for the MCA to measure the ischemic core rCBF and the second 3 mm posterior and S mm lateral to the bregma, to measure the penumbral rCBF (Buchan et aI., 1992) . The dura was not breached and the LDF probe was advanced to the dura surface without indenting the underlying cortex. There were five treatment groups: (1, 2) ischemia of l.S-h duration, with saline or SNX-l11 (S mglkg in 1 ml of saline) infused i. v. over 30 min at the beginning of reperfusion; (3, 4) ischemia of 2-h duration, with saline or SNX-Ill (S mg/kg in 1 ml of saline) infused i.v. over 30 min starting 60 min following MCAo; and (S) the same protocol as for group 4, except that i. v. norepi nephrine (NA), 10 fLg/ml, was infused at a variable rate (0.2-0.6 ml/h for 60--90 min) to support mean arterial pres sure above 100 mm Hg.
Twenty-four hours following the onset of ischemia, an imals were anesthetized, brains were removed, 20-fLm thick frozen sections were cut, and coronal sections were saved at SOO fLm intervals, stained with hematoxylin and eosin, and examined for neocortical infarction by light microscopy. The infarcted area of each section was traced using an image processing system and the infarct volume (mm3) was calculated.
Differences in infarct volume and CBF with different treatments were examined by onecway analysis of vari ance followed by post hoc Tukey procedures. A p value of <O.OS was taken as determining statistically significant differences. A priori sample size calculation for focal in farction with 2 h of ischemia with a predicted volume of injury (180 ± 30 mm3), (Xue et aI., 1994) indicated that, to avoid missing differences between groups of IS% (ex O.OS, 13 = 0.2), five animals were needed per group.
RESULTS
Morbidity and mortality
Global ischemia. All 11 saline-treated and all 10 rats treated with SNX-lll at 24 h survived 7 days of reperfusion, but 2 of 13 rats treated with SNX-l11 at 6 h died, for reasons that were not clear, by 24 h following infusion of the drug. Behavioral effects were particularly obvious in those rats treated at 6 h following reperfusion, with splaying of the hind limbs and tremor in the forelimbs, with shaking of the head but without loss of consciousness. These behavioral effects persisted for 3 to 6 h. Those an imals treated at 24 h had less obvious behavioural disturbances.
The temperature was successfully maintained fol lowing global ischemia with a rectal temperature of 37.5 ± OSC, although those animals subsequently given SNX-l11 (at 6 or 24 h) had to be heated for longer durations than those given saline; neverthe less, normothermia was carefully maintained by ex ternal heating for up to 6 h following SNX-l11 treat ment. In a forebrain feasibility study using Wistar rats following SNX -111 infusion, blood pressure had a mild tendency to fall from a mean arterial blood pressure of approximately 100 to 80 mm Hg. There was no adverse effect on blood gases. There was no correlation of the degree of behavioral effect or the duration of external heating with neuropro tection in the study reported here.
Two-hour focal ischemia "pilot study." Follow ing an i.v. "bolus" infusion of SNX-ll1 (5 mg/kg), the arterial blood pressure promptly fell to a mean of 65 ± 22 mm Hg (n = 6). In the 2-h focal pilot study with SNX-111 given as a bolus infusion (re sulting in hypotension), the CBF dropped from 8-10 to 2-3% (p < 0.01). This low flow persisted for the whole second hour of ischemia, and even after un clipping the MCA (at 2 h), the reperfusion flows were reduced to 15% (vs. 60% in controls) in the core and 26 versus 84% on the edge (p < 0.01). This effect was transient, and by 24 h, blood flow to both the core and the edge had fully recovered.
Focal ischemia. In the focal ischemic studies, we therefore resorted to slow infusions of SNX-111 in these experiments and the mean arterial blood pres sure fell from a baseline of 150--155 mm Hg (groups 2 and 4) to an initial mean of 90--100 ± 20 mm Hg at the onset of SNX-l11 infusion, but by the end of ischemia, it had recovered to 147 ± 30 mm Hg (group 2) and 123 ± 13 mm Hg (group 4). Animals with N A infusion to support their blood pressure had a mean arterial pressure of 110--120 mm Hg throughout (n = 5). Norepinephrine infusions, in progressively smaller doses, were needed to main tain the blood pressure for approximately 90 min following SNX-lll infusion and prevented it falling by more than 20 mm Hg at any stage. There was no animal mortality prior to death at 24 h. SNX-ll1 seemed to have less severe behavioral side effects (compared with global ischemia), although a mild sedative effect was noticed. Physiological condi tions (Po 2 , Pco 2 , pH, glucose, and hematocrit) for the five groups of focal animals were measured. The Pco 2 values were slightly higher, ranging from 49-52 mm Hg, which is what we expect in the SHR animal (Buchan et aI., 1992) with carotid and MCA occlusion, but otherwise, no significant differences were seen in baseline parameters among the five groups (Table 1) . Table 2 shows the blood flow in both the core area and the edge region for the focal experiments. (9) n/a 46 ± 5 3. Saline (6) n/a 45 ± 6 4. SNX (5) n/a 45 ± 10 5. SNX-Ill x NA (5) n/a 47 ± 5 BP, blood pressure; n/a, not applicable.
CBF measurements
Relative core and edge CBF was initially compara ble in all groups, i.e., prior to drug administration (6-10% of baseline). In group 2, with SNX-lll given at the time of reperfusion (90 min), there were no detrimental effects on rCBF. With slow SNX-111 infusion, with (group 5) or without (group 4) NA support, there were only mild falls (not significant) observed in the rCBF for both the edge and the core at the end of ischemia (2 h, i.e., following slow in fusion) and during early reperfusion, which were not detrimental to the histological outcome.
Histology Figure 1 displays the percentage of CAl cells in jured (after 10 min of global ischemia and 7 days of reperfusion) for each animal and the mean ± SD for each group. Animals treated with saline had 78 ± 13% CAl injury (n = 11). SNX-Ill given at 6 h reduced the percentage of injury to 35 ± 30% (n = 11; p < 0.01), and animals treated at 24 h had 50 ± 29% injury (n = 10; p < 0.05). Six of II animals treated at 6 h, and 5 of 10 animals treated at 24 h, had a marked cytoprotective effect, with <40% of the CAl cells injured at 7 days (Fig. 1) , compared to the 11 saline-treated rats. Injury in the cortex and striatum with 10 min of global ischemia was too slight to determine whether or not SNX-111 pro tected either cortex or striatum. Figure 2 displays the infarct volumes after focal ischemia for each animal and the mean infarct vol ume for each group (mean ± SD). In the 1.5-h focal ischemia groups, saline controls had 138 ± 32 mm3 of infarct volume (n = 9). With SNX-ll1 infusion, the infarct volume was reduced significantly, to 76 ± 25 mm3 (n = 9; p < 0.001). The mean infarct for saline-treated animals was 211 ± 51 mm3 (n = 6) following 2 h of ischemia. For those animals with 2 h of focal ischemia treated with slow infusion of SNX-III, the mean infarct was reduced to 126 ± 50 mm3 (n = 5; p < 0.05). The SNX-l11 treatment group supported with NA had a mean infarct of 141 ± 22 mm3 (n = 5; p < 0.05). Infarction was signif- icantly reduced by SNX-III (with or without NA), by 35-40%, despite the fact that the blood flows were clearly reduced to levels that would predict that the ischemic cortex would not survive, indicat ing that the therapy salvaged tissue at risk of pan necrosis.
DISCUSSION
These data demonstrate that (a) a single i. v. dose of the synthetic w-conopeptide SNX-III is able to inhibit the loss of CA I pyramidal cells, in the dorsal hippocampus, even when first administered 24 h following the insult; (b) delayed treatment with SNX-Ill can attenuate the volume of neocortical infarction in a model of focal ischemia that ordinar ily produces extremely consistent volumes of neo cortical damage; (c) although our initial pilot results were confounded by a drug-induced hypotensive ef fect that reduced rCBF during the last hour of isch emia and attenuated the reperfusion following clip removal, there was still evidence of cytoprotection; (d) giving SNX-I i I slowly produced less significant falls in blood pressure and achieved consistently less infarction in the absence of temperature reduc tions; (e) giving concurrent therapy with NA, while improving the blood pressure, may have induced cerebral vasoconstriction and therefore failed to im-prove CBF significantly; and (f) while there is little in the way of protection to the initial 100 mm3 of neocortical infarction judged to be in the core re gion of ischemia in this model, the tissue "on the edge," or where ischemia is dense, is salvaged with the use of this N -type Ca 2 + channel blocker despite a delayed treatment paradigm.
The synthetic w-conopeptide SNX-III has been shown by receptor autoradiography to bind to cells in the cortex, caudate, and hippocampus (Miljanich et aI., 1991) . It inhibits depolarization-induced Ca 2 + currents through neuronal voltage-sensitive Ca 2 + channels of the N type (Tsien et aI., 1988; Wagner et aI., 1988) typically found in the presynaptic bou ton (Reynolds et aI., 1986; McCleskey et aI., 1987) and, by blocking Ca 2 + entry into the presynaptic terminal, can prevent neurotransmitter release into the extracellular compartment (Dooley et aI., 1988; Newcomb and Palma, 1992) . While in a provisional report Smith and Siesjo (1993) could show only a modest protective effect in CAl, they did see more robust protection in the neocortex with 6 h-delayed treatment with SNX-Ill. We have been able to demonstrate very striking neuroprotection with SNX-III at both 6-and 24-h postforebrain ischemia for the exquisitely sensitive CAl hippocampal cells, confirming the results of Valentino et aI. (1993) . In the focal ischemic paradigm where CBF reductions are exacerbated by hypotension, both during isch emia and at the time of reperfusion, there is still neocortical protection despite the adverse hemody namic effects.
Initially, it was thought that the inhibition of neu rotransmitter release, which includes an inhibition of both glutamate and NA release, was, respec tively, the likely explanation for the prevention of cell death (Smith and Siesj6, 1993; Valentino et aI., 1993) and blood pressure reduction (Bowersox et aI., 1992) . More recent data have demonstrated that SNX-lI1 is relatively less potent at inhibiting the release of glutamate (Gaur et aI., 1992) than the w-conopeptide SNX-230 (MVIIC) (Newcomb and Palma, 1992; Valentino et aI., 1993) . Paradoxically, this distinct Ca 2 + channel blocking agent (which preferentially blocks non-L and non-N Ca 2 + chan nels), while potently preventing neurotransmitter release, is singularly lacking in neuroprotective ef fects (Valentino et aI., 1993) . The observations that SNX-230, which is a more potent glutamate release inhibitor, fails to protect CAl cells and that SNX-111 treatment is more potent at 6 h and is equally effective at 24 h postischemia (and therefore 24 h from the time when extracellular glutamate release is at a maximum) infer that the neuroprotective mechanism obtained by SNX-111 is not directly re- 
SNX-111 (9)
Saline (6) SNX-111 (5) SNX-111 +NA(5) (Group3) ) lated to the inhibition of the large presynaptic re lease of extracellular glutamate (Benveniste et aI., 1984) . The implication is that either release during reperfusion, when injury evolves slowly, or postsynaptic events linked to N-type Ca 2 + channels (Jones et aI., 1989 ) may be what critically deter mines injury (or its reversibility). It has been reported that Ca 2 + concentrations in CAl neurons following 10 min of severe forebrain ischemia do not differ from those in normal controls until 24 h of recirculation (Siesjo, 1986; Deshpande et aI., 1987) but becomes excessive 24 h following recirculation, increasing further at 48 h, with signif icant CAl neuronal injury being manifest at 72 h of reperfusion. Thus, the conopeptide neuroprotection might be achieved by preventing postsynaptic Ca 2 + entry though N-type Ca 2 + channels in a manner similar to that observed with the AMPA antagonist NBQX, which can still afford neuroprotection in the hippocampus 12 h postischemically by preventing Ca 2 + entry through the ischemia-modified, but glutamate-regulated, AMP A receptor channel complex (Pelligrini Giampietro et aI., 1992) . Directly injecting magne sium into the CA 1 following 24 h of reperfusion is also potently cytoprotective by postsynaptic Ca 2 + channel blockade (Tsuda et aI., 1991) . It is known that N-type Ca 2 + channels are restricted largely to neurons (Hillyard et aI., 1992) and are approxi mately 24-fold more dense than nimodipine binding sites, which have been implicated both in transient focal ischemia (Hakim and Hogan, 1991) and in transient forebrain ischemia (Takizawa et aI., 1994) . While the primary physiological function of N-type Ca2+ channels may be to mediate transmitter re lease, in these pathological situations there may be J Cereb Blood Flow Me/ab, Vol. 14, No.6, 1994 (Group5) a postsynaptic site (possible upregulated or "isch emia modified") at which SNX-lli acts.
Unlike the L-type voltage-sensitive Ca 2 + channel blockers (Steen et aI., 1984; Ohta et aI., 1991) , both the AMPA antagonist, NBQX, and this w-conopep tide, SNX-ll1, afford dramatic cytoprotection of the CAl cells at a time point clearly dissociated from the early excitotoxic threat, through specific blockade of a subpopulation of Ca 2 + -permeable channels. Blocking these channels with SNX-230, which blocks both an SNX-111-sensitive N-type Ca 2 + channel site and a second, non-L-, non-N-type Ca 2 + channel, does not result in neuroprotection, suggesting that a very selective, site-specific block ade of Ca 2 + entry is necessary for neuroprotection. In a similar way, blocking both NMDA and AMP A receptor/channel complexes may simultaneously result in a loss of the cytoprotective effect of block ing AMPA receptors alone .
In conclusion, these data show that the N-type Ca 2 + channel blocker SNX-Ill, derived from the venom of the Conus magus snail, has potent neu roprotective effects up to 24 h after ischemia for CAl cells and, also, protects with a delayed treat ment paradigm in the cortex in the wake of transient focal ischemia. This links the molecular site of ac tion of SNX-Ill on the N-type Ca 2 + channel to the pathogenesis of delayed postischemic CAl and cor tical injury. Since this peptide works following markedly delayed administration (24 h) and has rel atively less effect on glutamate release compared to the nonneuroprotective conopeptide SNX-230, this argues against presynaptic glutamate release inhi bition as the mechanism of protection and suggests an action that may be postsynaptic. This work sup ports the concept of novel treatments for stroke be-ing developed from naturally occurring toxins, pro viding that untoward side effects such as blood pressure reductions, as seen here, can be avoided.
